|
| 37879537 | Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study. | Ophthalmol Retina | 2024 |
| 36729431 | Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. | JAMA Ophthalmol | 2023 |
| 37219555 | Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-Reply. | JAMA | 2023 |
| 36749332 | Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. | JAMA | 2023 |
| 34628066 | A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE). | Ophthalmol Retina | 2022 |
| 35708698 | Patient-Reported Outcome Measures in a Clinical Trial of the Port Delivery System With Ranibizumab. | JAMA Ophthalmol | 2022 |
| 35344528 | ASSESSMENT OF FLUORESCEIN ANGIOGRAPHY NONPERFUSION IN EYES WITH DIABETIC RETINOPATHY USING ULTRAWIDE FIELD RETINAL IMAGING. | Retina | 2022 |
| 35833805 | Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. | N Engl J Med | 2022 |
| 35980610 | Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. | JAMA Ophthalmol | 2022 |
| 35980608 | Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time. | JAMA Ophthalmol | 2022 |
| 35238910 | Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema Trial. | JAMA Ophthalmol | 2022 |
| 34762102 | Managing Center-Involved Diabetic Macular Edema With Good Visual Acuity. | JAMA Ophthalmol | 2022 |
| 34003936 | Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy. | Transl Vis Sci Technol | 2021 |
| 33713680 | Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V. | Am J Ophthalmol | 2021 |
| 33784735 | Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. | JAMA Ophthalmol | 2021 |
| 34967834 | Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments. | Transl Vis Sci Technol | 2021 |
| 34673898 | Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2021 |
| 33989683 | Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. | Ophthalmology | 2021 |
| 33956075 | Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2021 |
| 34003937 | Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial. | Transl Vis Sci Technol | 2021 |
| 31567817 | ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. | Retina | 2020 |
| 31999300 | Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. | JAMA Ophthalmol | 2020 |
| 32077907 | Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2020 |
| 31984762 | Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trial. | Clin Trials | 2020 |
| 33320223 | Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. | JAMA | 2020 |
| 32970136 | Interpreting Multiple Outcomes of Pupillary Light Reflex in Sport-Related Concussion in Adolescents. | JAMA Ophthalmol | 2020 |
| 32722799 | Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2020 |
| 32239195 | Are P Values Enough? | JAMA Ophthalmol | 2020 |
| 32402554 | Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol TÂ Extension Study). | Ophthalmology | 2020 |
| 29135802 | PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. | Retina | 2019 |
| 31647496 | Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2019 |
| 30096354 | Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. | Ophthalmology | 2019 |
| 31246237 | Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. | JAMA Ophthalmol | 2019 |
| 30807516 | PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? | Retina | 2019 |
| 30860555 | Errors in Analysis of Mean Deviations in Study of Photocoagulation vs Ranibizumab for Diabetic Retinopathy. | JAMA | 2019 |
| 31037289 | Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. | JAMA | 2019 |
| 30816936 | Incorrect Data in Supplement. | JAMA Ophthalmol | 2019 |
| 30347105 | Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. | JAMA Ophthalmol | 2019 |
| 30676635 | Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. | JAMA Ophthalmol | 2019 |
| 29127949 | Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. | JAMA Ophthalmol | 2018 |
| 30077569 | Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. | Am J Ophthalmol | 2018 |
| 30234859 | CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report. | Retina | 2018 |
| 30043039 | Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. | JAMA Ophthalmol | 2018 |
| 29980333 | Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes. | Ophthalmology | 2018 |
| 30318048 | Reply. | Ophthalmology | 2018 |
| 29392288 | Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Ophthalmol | 2018 |
| 29525602 | Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. | Ophthalmology | 2018 |
| 29625440 | Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. | Invest Ophthalmol Vis Sci | 2018 |
| 27993277 | Reply. | Ophthalmology | 2017 |
| 31047572 | Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. | Ophthalmol Retina | 2017 |